Investors
CSE: TELI
OTCQB: TELI
DOWNLOAD THE INVESTOR DECK
Our Track Record
The value of our technology innovation is backed by our financial performance:
- Positive revenue in our first full fiscal year (FY22)
- 375% growth in revenue from FY 2022 to FY 2023
We have also succeeded in commercializing our first product. Within a year of launch, our DirectInject-LC™ technology was deployed by 13 of the top 20 pharma companies in the world. This product is now globally globally distributed by METTLER TOLEDO, a market leader in scientific instrumentation. View the Press Release here
Our Leadership & Expertise
Scientific leadership includes:
- 2-time Nobel Prize Winner in Chemistry: Dr. Barry Sharpless (Advisor)
- Globally-recognized expert in process chemistry, automation, and self-driving labs: Dr. Jason Hein (CTO, Director)
- An R&D team that has collectively authored over 450 peer-reviewed publications and 34 patents
Highlights from our management team:
- Ex-president of METTLER TOLEDO AutoChem, the market leader in lab and automation tools for biopharmaceutical and chemical development, Henry Dubina (CEO, Chairman)
OUR PARTNERS & CLIENTS
Our clients include the biggest names in pharmaceutical development, along with key innovators in engineering and chemical manufacturing. We also collaborate closely to develop technology with instrumentation companies ( METTLER TOLEDO, Mott), government bodies (Natural Resources Canada, the Canadian Mining Innovation Commercialization Network: MICA), and academic institutions ( Scripps Research).
Our Intellectual Property
Our IP portfolio includes discoveries in both pharmaceutical and fine chemical manufacturing. We have patented scalable routes to indole-based therapeutics, and are pursuing two patents related to the supply of battery materials: one low-temperature route to produce lithium sulfide, and one efficient purification process for battery-quality lithium carbonate.
Our patenting activities place us among the 2% of Canadian SMEs to hold patents.
